✦ LIBER ✦

Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer

✍ Scribed by A. Buzdar; D. Hayes; A. El-Khoudary; S. Yan; P. Lønning; M. Lichinitser; R. Gopal; G. Falkson; K. Pritchard; A. Lipton; K. Wolter; A. Lee; K. Fly; R. Chew; M. Alderdice; K. Burke; P. Eisenberg

Book ID: 110334736
Publisher: Springer US
Year: 2002
Tongue: English
Weight: 130 KB
Volume: 73
Category: Article
ISSN: 0167-6806
DOI: 10.1023/a:1015229630260

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Phase II Trial of weekly pacl

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

✍ Giampietro Gasparini; Massimo Gion; Luigi Mariani; Paola Papaldo; Diana Crivella 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 222 KB

Randomized phase III trial of trastuzuma

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

✍ Kenichi Inoue; Kazuhiko Nakagami; Mitsuhiro Mizutani; Yasuo Hozumi; Yasuhiro Fuj 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 368 KB

Pegase 03: a prospective randomized phas

Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer

✍ Biron, P; Durand, M; Roché, H; Delozier, T; Battista, C; Fargeot, P; Spaeth, D; 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 190 KB

Randomized phase III study comparing the

Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)

✍ Hiroyuki Narahara; Hiroyasu Iishi; Hiroshi Imamura; Akira Tsuburaya; Keisho Chin 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 415 KB

## Background Irinotecan hydrochloride and S-1, an oral fluoropyrimidine, have shown antitumor activity against advanced gastric cancer as single agents in phase I/II studies. The combination of irinotecan and S-1 (IRI-S) is also active against advanced gastric cancer. This study was conducted to c

A phase I/randomized phase II, non-compa

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

✍ Roger B. Cohen; Corey J. Langer; George Rajan Simon; Peter David Eisenberg; John 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 387 KB